Clinical effects of pulsed electromagnetic fields (PEMF) in patients with interstitial cystitis - a randomized controlled double-blind pilot stud

Clinical effects of pulsed electromagnetic fields (PEMF) in patients with interstitial cystitis - a randomized controlled double-blind pilot stud - PEMF-IC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030890

Enrollment

Registered

2022-12-08

Start date

2023-02-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N30.1

Interventions

Group 1: verum stimulation Group 2: sham stimulation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Interstiial cystitis (IC/BPS) ESSIC 2+3

Exclusion criteria

Exclusion criteria: - Change in therapy in the last 3 weeks before inclusion in the study - Patients who are not capable of giving their own consent - Patients who are physically or mentally unable to use the device themselves - Patients with cardiac pacemakers, defibrillators or other active implants - Patients with magnetic implants (implants not compatible with MRI) - Patients receiving corticosteroid injections - Patients in pregnancy and lactation - Patients with tumor diseases - Patients with a tendency to bleed

Design outcomes

Primary

Measure	Time frame
Improvement in the Global Response Assessment (GRA) compared to real and sham stimulation after 84 days of treatment.	—

Secondary

Measure	Time frame
Comparison of verum/sham stimulation relative to baseline after 84 days of treatment with PEMF: - Reduction of pain measured with NRS (Numerical Rating Scale 0-10), Deutscher Schmerzfragebogen, Pain Detect and BPIC-SS (Bladder Pain/Interstitial Cystitis Symptom Score). - Reduction of the urge to urinate measured with BPIC-SS and OAB-q SF (OverActive Bladder questionnaire Short Form) - Reduction of the feeling of pressure in the bladder measured with BPIC-SS. - Reduction of micturition frequency during the day and at night via a micturition protocol. - Increase in functional bladder capacity measured for 3 days (at the weekend) before inclusion in the study and 3 days at the end of the intervention after 79 to 82 days (at the weekend) with a voiding protocol. - Improvement in quality of life measured by OAB-q SF and BPIC-SS. Comparison of verum/sham stimulation relative to baseline after 28 days of treatment with PEMF	—

Measure

Time frame

Comparison of verum/sham stimulation relative to baseline after 84 days of treatment with PEMF: - Reduction of pain measured with NRS (Numerical Rating Scale 0-10), Deutscher Schmerzfragebogen, Pain Detect and BPIC-SS (Bladder Pain/Interstitial Cystitis Symptom Score). - Reduction of the urge to urinate measured with BPIC-SS and OAB-q SF (OverActive Bladder questionnaire Short Form) - Reduction of the feeling of pressure in the bladder measured with BPIC-SS. - Reduction of micturition frequency during the day and at night via a micturition protocol. - Increase in functional bladder capacity measured for 3 days (at the weekend) before inclusion in the study and 3 days at the end of the intervention after 79 to 82 days (at the weekend) with a voiding protocol. - Improvement in quality of life measured by OAB-q SF and BPIC-SS. Comparison of verum/sham stimulation relative to baseline after 28 days of treatment with PEMF

—

Countries

Germany

Contacts

Public ContactBjörn Theodor Kaftan

Städtisches Klinikum Lüneburg

Bjoern.Kaftan@klinikum-lueneburg.de+494131770

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026